Poolbeg Pharma #POLB August 2023 – CEO Jeremy Skillington talks to Alan Green August 7, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg CEO Jeremy Skillington talks to Alan Green in this August 2023 interview, and explains the company’s ‘capital light’ model that is giving the group a real market advantage. Jeremy then covers the developments this year with Poolbeg’s flagship POLB001 asset towards a blockbuster treatment for severe influenza, and the expansion of application into oncology and obesity. We then discuss joint ventures with AnaBio Technologies in the EncOVac consortium and the Cytoreason AI collaboration, before…

Poolbeg Pharma #POLB – Influenza Artificial Intelligence model build completed & on track to deliver outputs in Q2 2023 November 29, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that, further to its announcement in March 2022 , the construction of the computational artificial intelligence (AI) influenza disease model has been completed by CytoReason Limited (‘CytoReason’), indicating that it is on track to deliver outputs in Q2 2023. The model aims to unlock clinically meaningful insights into influenza infection…

Poolbeg Pharma #POLB – Interim results for the six months to 30 June 2022 September 6, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces its unaudited interim results for the six months to 30 June 2022. Financial & Operational Highlights • Well capitalised with a strong cash balance of £18.9m as at 30 June 2022 • Significant progress made on developing POLB 001, a treatment for severe influenza – LPS human challenge trial commenced…

A landmark year for Poolbeg Pharma #POLB – Alan Green talks to CEO Jeremy Skillington July 29, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

A landmark year for Poolbeg Pharma #POLB – Alan Green talks to CEO Jeremy Skillington, who takes us through what has been a very eventful year since the IPO. At 01:58 we discuss the flagship asset POLB 001, which reached a major milestone last week as it commenced a human challenge trial. At 05:00 Jeremy provides an overview of two collaborations in Artificial Intelligence and how Poolbeg will use these pioneering approaches to identify new treatments for…

Poolbeg Pharma #POLB August 2023 – CEO Jeremy Skillington talks to Alan Green August 7, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma #POLB – Influenza Artificial Intelligence model build completed & on track to deliver outputs in Q2 2023 November 29, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma #POLB – Interim results for the six months to 30 June 2022 September 6, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

A landmark year for Poolbeg Pharma #POLB – Alan Green talks to CEO Jeremy Skillington July 29, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Address

Contact

Social

LEGAL